Blueprint Medicines Acquires Lengo Therapeutics

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Foundation Medicine Acquires Lexent Bio, Inc.

June 13, 2020

Biotechnology

Foundation Medicine has completed the acquisition of Lexent Bio, Inc., a California-based precision oncology company developing multiomics liquid biopsy platforms. The deal will accelerate Foundation Medicine's liquid biopsy research and development—incorporating low-pass WGS and methylation analysis into new assays—to expand diagnostic capabilities and support therapeutic development and earlier-stage patient monitoring.

Aileron Therapeutics Acquires Lung Therapeutics

October 31, 2023

Biotechnology

Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.

Graphite Bio Completes Merger with LENZ Therapeutics; Combined Company to Trade as LENZ

March 21, 2024

Biotechnology

LENZ Therapeutics completed its previously announced merger with Graphite Bio and will commence trading on Nasdaq under the ticker LENZ. The transaction included a 1-for-7 reverse stock split, a special cash dividend, and a concurrent $53.5 million PIPE from a syndicate of healthcare investors, leaving the combined company with approximately $210 million in cash to support late-stage CLARITY Phase 3 readouts and planned NDA submission in mid-2024.

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.